Dendritic Cell-T Cell Crosstalk Mediated Cancer Immunotherapy

Ying Cai; Jiameng Chen; Yaping Li

doi:10.1002/exp2.70134

Exploration ›› 2026, Vol. 6 ›› Issue (2) :70134 DOI: 10.1002/exp2.70134

COMMENTARY

Dendritic Cell-T Cell Crosstalk Mediated Cancer Immunotherapy

Ying Cai ¹^,²
, Jiameng Chen ¹^,²
, Yaping Li ¹^,²

Author information +

History +

PDF (749KB)

Cite this article

Download citation ▾

Ying Cai, Jiameng Chen, Yaping Li. Dendritic Cell-T Cell Crosstalk Mediated Cancer Immunotherapy. Exploration, 2026, 6 (2) : 70134 DOI:10.1002/exp2.70134

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	S. Du, J. Yan, Y. Xue, Y. Zhong, and Y. Dong, “Adoptive Cell Therapy for Cancer Treatment,” Exploration 3 (2023): 20210058, https://doi.org/10.1002/EXP.20210058.

[2]	K. Ai, B. Liu, X. Chen, et al., “Optimizing CAR-T Cell Therapy for Solid Tumors: Current Challenges and Potential Strategies,” Journal of Hematology & Oncology 17 (2024): 105, https://doi.org/10.1186/s13045-024-01625-7.

[3]	G. Morad, B. A. Helmink, P. Sharma, and J. A. Wargo, “Hallmarks of Response, Resistance, and Toxicity to Immune Checkpoint Blockade,” Cell 184 (2021): 5309–5337, https://doi.org/10.1016/j.cell.2021.09.020.

[4]	M. J. Pittet, M. Di Pilato, C. Garris, and T. R. Mempel, “Dendritic Cells as Shepherds of T Cell Immunity in Cancer,” Immunity 56 (2023): 2218–2230, https://doi.org/10.1016/j.immuni.2023.08.014.

[5]	J. Yu, H. Sun, W. Cao, Y. Song, and Z. Jiang, “Research Progress on Dendritic Cell Vaccines in Cancer Immunotherapy,” Experimental Hematology & Oncology 11 (2022): 3, https://doi.org/10.1186/s40164-022-00257-2.

[6]	I. Mellman, D. S. Chen, T. Powles, and S. J. Turley, “The Cancer-Immunity Cycle: Indication, Genotype, and Immunotype,” Immunity 56 (2023): 2188–2205, https://doi.org/10.1016/j.immuni.2023.09.011.

[7]	C. S. Garris, S. P. Arlauckas, R. H. Kohler, et al., “Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12,” Immunity 49 (2018): 1148–1161.e7, https://doi.org/10.1016/j.immuni.2018.09.024.

[8]	Y. Shapir Itai, O. Barboy, R. Salomon, et al., “Bispecific Dendritic-T Cell Engager Potentiates Anti-Tumor Immunity,” Cell 187 (2024): 375–389.e18, https://doi.org/10.1016/j.cell.2023.12.011.

[9]	S. Zhou, M. Liu, F. Ren, X. Meng, and J. Yu, “The Landscape of Bispecific T Cell Engager in Cancer Treatment,” Biomarker Research 9 (2021): 38, https://doi.org/10.1186/s40364-021-00294-9.

[10]	S. C. Eisenbarth, “Dendritic Cell Subsets in T Cell Programming: Location Dictates Function,” Nature Reviews Immunology 19 (2019): 89–103, https://doi.org/10.1038/s41577-018-0088-1.

[11]	V. Bhandarkar, T. Dinter, and S. Spranger, “Architects of Immunity: How Dendritic Cells Shape CD8 + T Cell Fate in Cancer,” Science Immunology 10 (2023): eadf4726, https://doi.org/10.1126/sciimmunol.adf4726.

[12]	P. S. L. Schäfer, D. Dimitrov, E. J. Villablanca, and J. Saez-Rodriguez, “Integrating Single-Cell Multi-Omics and Prior Biological Knowledge for a Functional Characterization of the Immune System,” Nature Immunology 25 (2024): 405–417, https://doi.org/10.1038/s41590-024-01768-2.

[13]	L. C. Chen and Y. Y. Chen, “Outsmarting and Outmuscling Cancer Cells With Synthetic and Systems Immunology,” Current Opinion in Biotechnology 60 (2019): 111–118, https://doi.org/10.1016/j.copbio.2019.01.016.